electroCore Lifts 2026 Revenue Outlook to Over 30% Growth After Q2 Sales Jump 28%; Targets Positive EBITDA by Q3 2027
ECOR sits 61% above its 52-week low of $4.16.
Summary
electroCore posted Q2 2026 revenue of $9.5 million, a 28% year-over-year increase, and raised its full-year guidance to more than 30% growth. The company also set a target for positive Adjusted EBITDA in Q3 2027, a critical milestone given earlier going-concern concerns.
Key Events · Earnings and Guidance · ECOR
-
Q2 Revenue Up 28% to $9.5M
Net sales rose 28% year-over-year to $9.5 million, propelled by U.S. prescription sales through the VA channel and direct-to-consumer Truvaga. The Quell product line stood out, with revenue surging 700% to $1.3 million.
-
Full-Year Guidance Raised to >30% Growth
Reflecting confidence in the commercial restructuring and VA momentum, management lifted 2026 revenue guidance to greater than 30% annual growth over 2025, up from the prior implied outlook.
-
Positive Adjusted EBITDA Targeted for Q3 2027
For the first time, the company laid out a timeline to profitability, projecting positive Adjusted EBITDA in the third quarter of 2027, backed by cost-saving initiatives and scaling revenue.
-
Cash Position of $10.0M at Quarter-End
Cash, equivalents, and marketable securities stood at $10.0 million on June 30, 2026, down from $11.6 million at year-end 2025. Additional capital will likely be needed before the company reaches breakeven.
Analysis · ECOR · Industrial Applications And Services
A strong second quarter saw revenue climb 28% to $9.5 million, fueled by VA prescription sales and accelerating Quell adoption. In response, management raised the full-year 2026 growth target to more than 30% and, for the first time, committed to reaching positive Adjusted EBITDA by the third quarter of 2027. This marks a decisive pivot from the going-concern warnings that shadowed recent filings — the upgraded outlook and commercial restructuring now chart a credible path to breakeven, even though cash remains tight at $10 million. The market will have to balance the growth trajectory against the likely need for additional capital before profitability arrives.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 29.5% of the 1457 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ECOR was trading at $6.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $60.4M. The 52-week trading range was $4.16 to $10.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.